LadRx Corporation LADX

LADX Company Overview

LadRx Corporation (LadRx, ticker LADX) is a clinical-stage biopharmaceutical company focused on the development of oncology therapeutics. The company operates within the biotechnology and pharmaceutical industry, with activities centered on advancing drug candidates for the treatment of cancer, particularly solid tumors with significant unmet medical need. LadRx does not currently generate product revenue and relies primarily on equity financing, licensing arrangements, and strategic transactions to fund operations.

The company’s primary historical asset has been aldoxorubicin, a modified form of the chemotherapy drug doxorubicin designed to improve targeted delivery and reduce systemic toxicity. LadRx evolved from its predecessor, CytRx Corporation, which was founded in 1986 and rebranded to LadRx Corporation in 2023 as part of a strategic realignment emphasizing oncology-focused drug development and asset monetization. The company’s positioning has been as a niche oncology developer seeking value through selective clinical advancement, licensing, or asset sales rather than large-scale commercialization.